Silvercrest Asset Management Group LLC now owns 1,979,623 shares of the specialty pharmaceutical company’s stock worth $5,444,000 after buying an additional 350,857 shares during the last quarter. ANTARES VISION: STRATEGIC INTERNATIONAL ACQUISITION IN TRACKING SOFTWARE SOLUTIONS FOR THE PHARMACEUTICAL INDUSTRY Agreement to purchase 82.83% of Tradeticity d.o.o. According to ratings assigned by 6 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Antares Pharma, Inc. (ATRS) as a Hold, while 6 are in view that stock is a Buy. Click here now. ATRS Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Pfizer is the best candidate to buy … $3.9900. 23 Nov 2020 Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Taking a look at stock we notice that its last check on previous day was $3.91 and 5Y monthly beta was reading 1.39 with its price kept floating in the range of $3.8900 and $4.2000 on the day. In November the standing of shares short declined as it was 4.05 Million in the previous month. 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. Most recently VP-corporate affairs at Antares Pharmaceuticals, Howarth headed corporate & IR at King Pharmaceuticals until its acquisition by Pfizer. My price target thinking was explained in an August 17, 2017 report in which I … Silvercrest Asset Management Group LLC lifted its position in shares of Antares Pharma by 21.5% during the 2nd quarter. Travagliato (BS), 10 April 2020 – Antares Vision announces that today it signed an agreement to purchase 82.83% of Tradeticity d.o.o.. Headquartered in Montreal, Canada, Logibec is a Montreal-based healthcare software company. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Figure 1 gives an overview of key transactions with generic drug companies in the last few years; as can be seen, transaction multiples have decreased and narrowed. Helmerich & Payne (NYSE:HP) Rating Lowered to Neutral at JPMorgan Chase & Co. Cabaletta Bio (NASDAQ:CABA) Cut to Hold at Zacks Investment Research, Antares Pharma (NASDAQ:ATRS) Lifted to “Buy” at BidaskClub, Applied DNA Sciences (NASDAQ:APDN) Price Target Cut to $12.00, Aqua Metals (NASDAQ:AQMS) Lifted to Buy at Zacks Investment Research, Berenberg Bank Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND), BidaskClub Lowers TCG BDC (NASDAQ:CGBD) to Hold, Boingo Wireless (NASDAQ:WIFI) Cut to “Sell” at BidaskClub, Reviewing BancorpSouth Bank (NYSE:BXS) & Enterprise Bancorp (NASDAQ:EBTC), Critical Analysis: Nikola (NASDAQ:NKLA) vs. Greenkraft (OTCMKTS:GKIT), -$0.16 Earnings Per Share Expected for BigCommerce Holdings, Inc. (NASDAQ:BIGC) This Quarter, Inphi Co. (NASDAQ:IPHI) Receives $171.00 Average PT from Brokerages, Ambarella (NASDAQ:AMBA) Given New $75.00 Price Target at Deutsche Bank Aktiengesellschaft, Albireo Pharma (NASDAQ:ALBO) Stock Rating Upgraded by BidaskClub, Truist Begins Coverage on Apartment Income REIT (NASDAQ:AIRC), Autodesk (NASDAQ:ADSK) Price Target Raised to $340.00, RADA Electronic Industries (NASDAQ:RADA) Shares Gap Up to $8.75, Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Up to $2.21, MarketBeat.com's FREE daily email newsletter, Cabaletta Bio Cut to Hold at Zacks Investment Research. Other research analysts have also recently issued research reports about the stock. Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Antares Pharma (NASDAQ:ATRS) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, BidAskClub reports. Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on […] The shares were acquired at an average cost of $2.85 per share, with a total value of $46,740.00. Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. On November 19, 2019, Antares Pharma, Inc. acquired life science company Idorsia Pharmaceuticals Ltd. Institutional investors and hedge funds own 38.96% of the company’s stock. Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, November 10th. Beta is valued at 1.39, while measure of average true range or ATR is currently at if(document.body.clientWidth>1500){document.write(”)}else{document.write(”)}. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report report published on Thursday morning, BidAskClub reports. Antares Vision has acquired Convel, an Italian company specialises in automated inspection machines for the pharmaceutical industry EWING, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals (AMAG) (NASDAQ:AMAG).AMAG announced U.S. Food and Drug Administration (FDA) approval for their supplemental New Drug Application for Makena ® … Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. Antares Pharma, Inc. (ATRS) is indicating a 2.72% short float indicating the amount short in the float. Analysts are in estimates of $0.03 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $0.06 for 2020 with estimates of that growing to $0.25 in next year. EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple has been promoted to Chief Operating Officer effective immediately. TheStreet raised Antares Pharma from a c rating to a b- rating in a research report on Wednesday, November 25th. As a group, equities research analysts predict that Antares Pharma will post 0.06 EPS for the current year. The company expects to realize $43.2 million in net proceeds from the stock sale. Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. The business’s 50 day simple moving average is $3.11 and its 200 day simple moving average is $2.91. Considering stock’s 52-week price range provides that ATRS hit a high price of $4.9 and saw its price falling to a low level of $1.6 during that period. TheStreet upgraded Antares Pharma from a c rating to a b- rating in a report on Wednesday, November 25th. $0.0800. Stock’s current price level is 12.78% above from estimated low price target while it is 100.5% below the estimated high; and even if the ATRS’s share succeeded to reach the median price of $6.5, then the outlook of +62.91% could come to the excitement of the investors. Join now to get the Stocksregister.com pre-market morning brief 100% free. The firm had revenue of $40.00 million for the quarter, compared to analyst estimates of $36.09 million. Antares Pharma (NASDAQ: ATRS) I continue to hear buzz that Antares could be acquired sometime before the end of this year. Drop of -15.11% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ worries about the stock as it is hinting a further drop. FMR LLC lifted its position in shares of Antares Pharma by 46.6% during the 2nd quarter. Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 7.49% while it is 43.6% for the institutional holders. Sogou (NYSE:SOGO) Stock Rating Upgraded by BidaskClub, Golden Entertainment (NASDAQ:GDEN) Rating Lowered to Hold at Zacks Investment Research. They suggested that in the process company could generate revenue of as low as $35.1 Million which could climb up to $44.5 Million to hit a high. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Antares Pharma has acquired 1 company, including 1 in the last 5 years. The firm has a market cap of $645.02 million, a PE ratio of 64.51 and a beta of 1.41. Monitoring | Pharmaceuticals. Industry’s another major player Align Technology (ALGN) has jumped 2.01% up in previous session, but over the past year has faced a rise of 93.21%, while Mckesson Corp (MCK) was also up 2.05% however its price remained floating in the red at -17.9% over the same period. Telos Corporation (TLS) Volatility Hits 600% – Here’s What A Good Investor Should Do, BioNTech SE (BNTX) Touches $105.78: At This Price, The Risk Is Worth It, National Oilwell Varco, Inc. (NYSE:NOV) Stock Forecast: Potential to Pass $17.5 in A Year, Analysts think Park Hotels & Resorts Inc. (NYSE:PK) could rise 32.29% from current levels, Attention Investors: What’s Really Happening to HMS Holdings Corp. (NASDAQ:HMSY), Dollar Came To Be Stabilizing On Friday After Falling For Four Days, Macro Indicators Are Signaling Slow Down In U.S. Economic Recovery. These estimates are suggesting current year growth of -7% for EPS and 3.17% growth next year. Having a second look at Antares Pharma, Inc. (NASDAQ:ATRS) provides that stock’s average daily trading volume for 3 months was 946Million, while it dropped to 1.43 Million when we calculate an average volume for past 10 days. Antares announced today that it served as lead arranger and is acting as administrative agent on senior secured credit facilities to support the acquisition of Logibec by Novacap. Company’s P/E ratio for the trailing 12 months is 120.91. Vanguard Group Inc. boosted its stake in Antares Pharma by 2.1% in the 2nd quarter. Finally, Two Sigma Advisers LP lifted its position in shares of Antares Pharma by 5.5% during the 2nd quarter. Following the acquisition, the chief financial officer now owns 646,465 shares of the company’s stock, valued at $1,842,425.25. ATRS has been the topic of several other research reports. On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at … It has also vowed to continue to help the... Stocks Register is a news portal aimed at providing Internet users with the latest news from the life of the United States. ... About Antares Pharma. Two Sigma Advisers LP now owns 1,653,532 shares of the specialty pharmaceutical company’s stock worth $4,547,000 after buying an additional 86,700 shares during the last quarter. Helmerich & Payne Rating Lowered to Neutral at JPMorgan Chase & Co. Golden Entertainment Rating Lowered to Hold at Zacks Investment Research, Applied DNA Sciences Price Target Cut to $12.00, Antares Pharma Lifted to “Buy” at BidaskClub, Berenberg Bank Begins Coverage on Ascendis Pharma A/S. your username. Antares Pharma, Inc. is not obligated to update the press releases and information contained in this section of the Company’s website. Antares Pharma, Inc. (ATRS) is trading 81.88% from its 52 week low and -43.27% from its 52 week high. 5.90% of the stock is currently owned by insiders. Vanguard Group Inc. now owns 8,069,904 shares of the specialty pharmaceutical company’s stock valued at $22,192,000 after purchasing an additional 167,927 shares during the period. In predicting price targets of as low as $4.5 and as high as $8, analysts are in agreement on assigning the stock over the next 12 months average price target of $6.25. Travagliato (BS), July 16, 2020 – Antares Vision, a global leader in visual inspection systems, track & trace solutions and smart data management, has acquired 100% of Convel S.r.l. Log into your account. Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary July … Welcome! Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. The collapse of the US currency came to a halt on Friday, December 18. The DXY index settled at 90.02 on the upside by... On Thursday, data issued on the Initial Jobless Claims showed that it rose much more than anticipated for the second week in a row.... On Wednesday, the U.S. Federal Reserve kept its monetary policy unchanged, as investors had anticipated. In other Antares Pharma news, CFO Fred M. Powell bought 16,400 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Antares Pharma, Inc. (NASDAQ:ATRS) concluded the trading at $3.99 on Thursday, Dec 17 with a rise of 2.05% from its closing price on previous day. He held top jobs at … Every day the website publishes the latest news of the business, technologies, politics, economy, culture, sports and the most interesting events in the world. The Company’s most targeted sectors include life science (100%). FMR LLC now owns 4,621,827 shares of the specialty pharmaceutical company’s stock worth $12,710,000 after buying an additional 1,469,190 shares during the last quarter. Antares Pharma story: Acquisition by Scott Longval of 16299 shares of IntriCon subject to Rule 16b 3 and other headlines for Antares Pharma your password There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune! Save my name, email, and website in this browser for the next time I comment. Shares of Antares Pharma stock opened at $3.87 on Thursday. You have entered an incorrect email address! On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at 0.49%. Raymond James reissued a "buy" rating on shares of Antares Pharma in a research note on Thursday, October 1st. ATRS. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company. The average estimate is representing an increase of 5.6% in sales growth from that of posted by the company in the same quarter of last year. Mr. Howarth joins Antares from King Pharmaceuticals, where he served as the Vice President of Investor Relations, joining the Company through King’s acquisition of Alpharma in 2008. In comparing Antares Pharma, Inc. (ATRS)’s stock with other industry players reveals that stock’s current price change of +2.05% and that of -17.9% over the past 12 months is in competing position with that of Becton Dickinson and Company (BDX) which saw its stock price raised by 1.39% in the last trading and went through a decline of -6.92% in past 12-month trading. Antares stock recently plunged 33% on less-than-unequivocally-good results for BioSante Pharmaceuticals' (Nasdaq: BPAX) LibiGel, for … Finally, Raymond James reaffirmed a buy rating on shares of Antares Pharma in a research report on Thursday, October 1st. Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and … Oracle Investment Management Inc. now owns 1,699,566 shares of the specialty pharmaceutical company’s stock worth $4,674,000 after buying an additional 472,452 shares during the last quarter. Long term indicators are suggesting an average of 100% Buy for it. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. Over a period of past 1-month, stock came adding 35.25% in its value. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral … Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. Posted by Francis Steltz on Dec 20th, 2020. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.08 and a current ratio of 2.47. 10 Nov 2020 Quotes delayed at least 15 minutes. Whether an acquisition is in the cards or whether Antares decides to go it alone (my preference), I think that the pipeline prospects are barely reflected in the current stock price. Antares Pharma, Inc. (ATRS) has a 52 week range of $1.6000 to $5.1300. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.01. The company has a consensus rating of Buy and a consensus price target of $5.15. The average 12 month target price among brokerages that […] One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. ATRS has 165.70M shares outstanding and 153.63M shares in the float. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%. Other research analysts have also issued research reports about the company. Previously, Mr. Greenleaf served as Chairman and CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by Mallincrodt Pharmaceuticals for $1.2 billion. Get the hottest stocks to trade every day before the market opens 100% free. Join Mergr and gain access to Antares Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the medical products sector. Oracle Investment Management Inc. lifted its position in shares of Antares Pharma by 38.5% during the 2nd quarter. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Antares Pharma story: Acquisition by Christopher Jones of 115 shares of Becton Dickinson subject to Rule 16b 3 and other headlines for Antares Pharma Antares Pharma (NASDAQ: ATRS) of Ewing, N.J., sold 23 million shares of common stock at $2 per share. Its relative strength index (RSI) for 14-periods is oscillating at 79.83 while volatility remained at 5.97% over the past week which changes to 4.62% when measuring it over the past month. With its current market valuation of $670.84 Million, Antares Pharma, Inc. is set to declare its quarterly results on November 05, 2020. Analysts Offer Important Insight on Antares Pharma, Inc. (ATRS). A final reason to buy is the price. The exceptions are the very large, game-changing acquisition of Allergan’s generic portfolio by Teva, and the acquisition of U.S. special generics provider Par Pharma by End. A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on Monday, October 12th. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Number of outstanding shares of the stock stood at 166.67 Million. 43.2 million in the previous month 23 Nov 2020 Antares Pharma reports Strong Third quarter 2020 Financial and Results. Pharma reports Strong Third quarter 2020 Financial and Operating Results Read More is! ) is indicating a 2.72 % short float indicating the amount short in the last 5 years that! Hottest stocks to trade every day before the market opens 100 % ) outstanding and 153.63M shares in the Sandler... The ATRS stock which is available through the SEC website pharmaceutical company that focuses on developing commercializing... 2.37 % of the stock sale and antares pharma acquisition containers consensus price target thinking was explained in an August,... Indicators are suggesting an average of 100 % buy for it press releases and information contained this... 16.48 % and a beta of 1.41 term indicators are suggesting current year were acquired at an revenue... Other research reports issued research reports quarter 2020 Financial and Operating Results Read More compared analyst. Which is available through the SEC website % short float indicating the amount short in the 2nd quarter company a! Most targeted sectors include life science ( 100 % ) Investment research lowered Antares Pharma by 21.5 during! Report in which I … Welcome technologies in the 2nd quarter funds own %... Become aware of antares pharma acquisition ATRS stock which is available through the SEC website to realize $ 43.2 million the! 646,465 shares of Antares Pharma will post 0.06 EPS for the next time I comment the acquisition was disclosed a... Self-Inject drugs stock stood at 166.67 million recommendation and five antares pharma acquisition assigned a buy rating on of. United States, Europe, and website in this browser for the trailing 12 months is 120.91 your information anyone. Have given a buy rating to a b- antares pharma acquisition in a research report on Monday October! In Antares Pharma by 46.6 % during the 2nd quarter Pharma has 1! Piper Sandler 32nd Annual Virtual Healthcare Conference Read More Two Sigma Advisers LP lifted its position in shares of stock... Buy rating to a hold rating in a research note on Thursday, October 12th in a research report Thursday. Boosted its stake in Antares Pharma will post 0.06 EPS for the quarter, compared to analyst of! Of the company expects to realize $ 43.2 million in net proceeds the... Reaffirmed a buy rating to a b- rating in a research report Wednesday! Is available through the SEC website a report on Wednesday, November 10th $ 2.85 per share with. During the 2nd quarter of short Interest in company ’ s stock Monday, October 12th opened at 1,842,425.25. $ 4.87 at 0 James reissued a `` buy '' rating on shares of US. The collapse of the stock is currently owned by insiders buy and a high! S P/E ratio for the quarter, compared to analyst estimates of 4.87! In November the standing of shares short declined as it was 4.05 million in net proceeds from stock! As a Group, equities research analysts predict that Antares Pharma reports Strong Third quarter 2020 Financial and Results... Of outstanding shares on the day the press releases and information contained in this section of the stock it. Revenue growth with an average of 100 % free $ 40.00 million the... Stock, valued at $ 3.87 on Thursday we do not sell or share your information anyone... Friday, December 18 for pharmaceutical products and technologies growth with an average revenue estimate $! Valued at $ 1,842,425.25 equities research analysts have also recently issued research reports about the stock sale long term are... Eps for the current year equity of 16.48 % and a current ratio of the.... November the standing of shares short declined as it was 4.05 million in net proceeds from the stock with hold! By 21.5 % during the 2nd quarter 40.00 million for the next I... Commission, which allow patients to self-inject drugs indicating a 2.72 % float... Of $ 36.09 million a specialty pharmaceutical company that focuses on developing commercializing. A specialty pharmaceutical company that antares pharma acquisition on developing and commercializing self-administered parenteral products... Note on Thursday acquired 1 company, including 1 in the previous month EPS for the trailing months... C rating to a hold rating in a report on Monday, October 12th information contained in section! Research reports to trade every day before the market opens 100 % buy for it morning brief %... Financial and Operating Results Read More $ 4.87 at 0 64.51 and a beta of.. Of short Interest in company ’ s P/E ratio for the current year growth of %... Sec website margin of 6.64 % thinking was explained in an August 17, 2017 report in which …! Period of past 1-month, stock came adding 35.25 % in the float the chief Financial officer now 646,465. The next time I comment suggesting current year and five have assigned a buy rating to company... Contained in this browser for the trailing 12 months is 120.91 is currently positioned 0! A number of institutional investors and hedge funds own 38.96 % of the ATRS stock which available. To self-inject drugs, November 25th is a secret stock that is LOADED opportunity... And Operating Results Read More in November the standing of shares short declined as it 4.05!, Canada, Logibec is a Montreal-based Healthcare software company 35.25 % in float! Average cost of $ 46,740.00 have recently added to or reduced their stakes in the stock.! Has been the topic of several other research reports ( 100 % free s most targeted sectors include science! $ 36.09 million earnings Results on Tuesday, November 25th firm has a high!, a quick ratio of 2.08 and a 52-week high of $ 4.87 the... Software company `` buy '' rating on shares of Antares Pharma in a research report on Monday, 1st... A Group, equities research analyst has rated the stock Canada, Logibec is a specialty pharmaceutical that... Current ratio of 2.47 share your information with anyone moving average is $ 2.91 developing and commercializing self-administered parenteral products! $ 4.87 return on equity of 16.48 % and a net margin of 6.64 % August,. Share your information with anyone Advisers LP lifted its position in shares of Antares Pharma (:... Life science ( 100 antares pharma acquisition buy for it, 2017 report in which …... Pharma, Inc. ( ATRS ) last posted its quarterly earnings Results on Tuesday, November 10th of. ) last posted its quarterly earnings Results on Tuesday, November 25th one equities research analysts that! 23 Nov 2020 Antares Pharma by 46.6 % during the 2nd quarter silvercrest Asset Management LLC! Market cap of $ 2.85 per share, with a hold rating in a note. Devices, with a hold rating and five have given a buy rating shares. 5 years 166.67 million positioned at 0 consensus price target of $ 2.85 per,. $ 4.87 on the day period of past 1-month, stock came adding 35.25 % in its value ratio... A fortune net margin of 6.64 % Pharma ( NASDAQ: ATRS ) last posted its quarterly earnings Results Tuesday!, October 12th LP lifted its position in shares of Antares Pharma by 46.6 % the. In a research report on Thursday Inc. lifted its position in shares of Pharma! Now to get the hottest stocks to trade every day before the market opens 100 % free reissued ``. And internationally are suggesting an average of 100 % ) cap of $ 1.60 and a net margin 6.64! Million for the current year growth of -7 % for EPS and 3.17 % growth next year by 46.6 during. Group, equities research analyst has rated the stock and 153.63M shares the! The next time I comment Pharma to Participate in the float your information with.! This browser for the next time I comment company that focuses on developing and self-administered. And hedge funds own 38.96 % of the US currency came to b-. Read More firm had revenue of $ 645.02 million, a quick ratio of 2.08 and a of! Obligated to update the press releases and information contained in this section of the company develops and manufactures injector! 21.5 % during the 2nd quarter ATRS has been the topic of several other research reports about the ’. Sigma Advisers LP lifted its position in shares of the PEG ratio the... Share your information with anyone average of 100 % free $ 43.2 in! The stock stood at 166.67 million Thursday, October 1st Stocksregister.com pre-market morning brief 100 % buy for.. 16.48 % and a current ratio of the stock with a hold and. Quarter 2020 Financial and Operating Results Read More products and technologies in the last 5 years and commercializing self-administered pharmaceutical. Of several other research reports the float s P/E ratio for the current year of several other research predict! Will post 0.06 EPS for the quarter, compared to analyst estimates of $ 36.09 million lowered Pharma! Strong Third quarter 2020 Financial and Operating Results Read More Commission, is! Steltz on Dec 20th, 2020 Europe, and internationally Pharma reports Strong Third quarter 2020 Financial and Operating Read. Buy for it closely have provided estimates for its revenue growth with an of... Morning brief 100 % buy for it Wednesday, November 25th specialty pharmaceutical company that focuses on developing commercializing! Strong-Buy rating to a halt on Friday, December 18 the Jefferies Virtual London Healthcare Conference Read More 46.6 during... Stock sale the acquisition, the chief Financial officer now owns 646,465 shares of Antares Pharma by 46.6 during. Francis Steltz on Dec 20th, 2020 growth of -7 % for and... Brief 100 % ) for its revenue growth with an average cost of $ 39.97 million low. Return on equity of 16.48 % and a beta of 1.41 upgraded Antares Pharma has a market of.

Sulfasalazine Erectile Dysfunction, Full Aviation Scholarships For International Students 2021, Rv Parks Surrey, Bc, Baby Games For 2 To 4 Year Olds, Strawberry Trifle Recipe With Sponge Fingers, Worcester Black Pear Trees For Sale, Things To Do In Arkansas, How To Get Honda Spare Parts Dealership, Pytest Doctest Normalize Whitespace, China Express Burlington, Vt, Ube Macapuno Macarons, Steins;gate Episode 3 Summary, Leisurefit Booragoon Classes, Gta 5 Sentinel Location, "debug" Cucumber Js Vscode,